HER-3 strong membranous and weak to moderate cytoplasmic staining (× 200)

<p><b>Copyright information:</b></p><p>Taken from "Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas"</p><p>BMC Cancer 2006;6():46-46.</p><p>Published online 28 Feb 2006</p><p>PMCID:PMC1431553.</p><p>Copyright © 2006 Kountourakis et al; licensee BioMed Central Ltd.</p

Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas-2

<p><b>Copyright information:</b></p><p>Taken from "Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas"</p><p>BMC Cancer 2006;6():46-46.</p><p>Published online 28 Feb 2006</p><p>PMCID:PMC1431553.</p><p>Copyright © 2006 Kountourakis et al; licensee BioMed Central Ltd.</p>ction in the adenomatous part of lesion (× 200

Kaplan-Meier survival curve comparing overall survival estimation between low- and high-expressing E-cadherin groups.

<p>a) Patients with high tumor E-cadherin expression exhibit a higher probability of OS (69.6% vs. 44.3%, p = 0.05). b) There was no association between beta-catenin and OS (p = 0.16). c) Patients with high tumor EGFR expression had inferior 5-year overall survival compared with those with low tumor EGFR expression (27.7% vs. 54%, p = 0.029).</p

Multivariable 5-year overall survival (OS) analysis, by Cox regression.

<p>Multivariable 5-year overall survival (OS) analysis, by Cox regression.</p

Demographic, clinical and pathologic characteristics.

<p>Demographic, clinical and pathologic characteristics.</p

Kaplan-Meier survival curve comparing progression-free survival estimation between low- and high-expressing E-cadherin, beta-catenin and EGFR groups.

<p>a) Patients with high tumor E-cadherin expression exhibit a higher probability of PFS (59.7% vs. 40.6%, p = 0.04). b) Patients with low expression of beta-catenin trended towards worse PFS (p = 0.057). c) There was no association between EGFR expression and PFS (p = 0.49).</p

Prognostic Impact of Pretreatment Plasma Fibrinogen in Patients with Locally Advanced Oral and Oropharyngeal Cancer - Fig 1

<p><b>Receiver operating characteristic curves for pretreatment plasma fibrinogen predicting overall survival (A), and recurrence-free survival (B).</b> Using ROC curve analysis, a pretreatment plasma fibrinogen cutoff value of 447mg/dL was determined for both OS and RFS.</p

Kaplan–Meier estimates of the probability of recurrence-free survival in 183 patients with locally advanced OOSCC according to low and high pretreatment plasma fibrinogen.

<p>Kaplan–Meier estimates of the probability of recurrence-free survival in 183 patients with locally advanced OOSCC according to low and high pretreatment plasma fibrinogen.</p

Correlation between pretreatment plasma fibrinogen levels and clinicopathological parameters in 183 patients with oral and oropharyngeal cancer.

<p>Correlation between pretreatment plasma fibrinogen levels and clinicopathological parameters in 183 patients with oral and oropharyngeal cancer.</p

Univariate and multivariate analysis of prognostic factors for overall survival and recurrence-free survival in patients with oral and oropharyngeal cancer.

<p>Univariate and multivariate analysis of prognostic factors for overall survival and recurrence-free survival in patients with oral and oropharyngeal cancer.</p